Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Liu ZL, Liu PP, Bi XW, Lei DX, Wang Y, Li ZM, Jiang WQ, Xia Y (2019) Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: a SEER database analysis. Cancer Med 8(3):874–881
2. Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K, Serve H, Dührsen U, Hüttmann A, Thiel E, Dengler J (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial Blood. J Am Soc Hematol 124(26):3870–3879
3. Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-llovera F, Tormo M, Hernández-Rivas JM, García D (2013) Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer 119(9):1660–1668
4. Lacasce A, Howard O, Li S, Fisher D, Weng A, Neuberg D, Shipp M (2004) Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 45(4):761–767
5. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH (2013) Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 369(20):1915–1925